Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: Implications for adjuvant therapies

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5454-5461

  Yu, Duonan ^a   Dews, Michael ^a   Park, Andrea ^a   Tobias, John W ^a   Thomas Tikhonenko, Andrei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CD20 ANTIGEN; ESTROGEN RECEPTOR; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; MYC PROTEIN; RITUXIMAB;

ADJUVANT THERAPY; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MITOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR CELL; TUMOR REGRESSION;

ALLELES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, MYC; INTERLEUKIN-10; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; RECEPTORS, INTERLEUKIN; TAMOXIFEN; UP-REGULATION;

EID: 20644468601     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4197     Document Type: Article

References (41)

1. Cole MD. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet 1986;20:361-84.
2. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003;3:163-75.
3. Pelengaris S, Littlewood T, Khan M, Elia G, Evan GI. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-77.
4. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
5. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
6. Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer 2004;110:336-42.
7. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003;101:2797-803.
8. D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7:235-9.
9. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
10. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004;6:577-86.
11. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene 1999;18:5268-77.
12. Yu D, Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 2002;21:1922-7.
13. Yu D, Allman D, Goldscmidt M, Atchison M, Monroe JG, Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 2003;101:1950-5.
14. Littlewood TD, Hancock DC̀, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;33:1686-90.
15. Pajic A, Spitkovsky D, Christoph B, et al. Cell cycle activation by c-myc in a Burkitt lymphoma model cell line. Int J Cancer 2000;87:787-93.
16. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:3.
17. Bossy-Wetzel E, Green DR. Detection of apoptosis by Annexin V labeling. Methods Enzymol 2000;322:15-8.
18. Evan GI, Vbusden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
19. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991;173:1213-25.
20. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell-cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
21. Li YS, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med 1993;178:951-60.
22. Roussel F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992;89:1890-3.
23. Cervenak L, Morbidelli L, Donati D, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 2000;96:2568.
24. Neiman PE, Ruddell A, Jasoni C, et al. Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius. Proc Natl Acad Sci U S A 2001;98:6378-83.
25. Schuhmacher M, Kohlhuber F, Holzel M, et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 2001;29:397-406.
26. Staege MS, Lee SP, Frisan T, et al. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A 2002;99:4550-5.
27. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988;85:208-12.
28. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-93.
29. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol 2004;16:119-29
30. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
31. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAAKT). Eur J Cancer 2001;37:1316-9.
32. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996;2:1969-79.
33. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: Releasing a brake on immune responses against cancer? Cancer Cell 2004;5:111-2.
34. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
35. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996;88:809-16.
36. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
37. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A 1993;90:11267-71.
38. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-63.
39. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
40. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000;27:9-16.
41. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.